SEC Tracker
Get the app
TECX · XBRL financial data

Tectonic Therapeutic financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TECX's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Research and development4,390*6837,07414,3179,156*13,03617,18516,92716,341*20,87118,04817,443
Selling, general and administrative——9,9000*————————
General and administrative5,237*7,2584,3475,3204,835*5,2625,1474,9635,175*6,4306,1706,015
Total operating expenses9,627*7,94111,42119,63713,991*18,29822,33221,89021,516*27,30124,21823,458
Operating income (loss)(9,662)*(7,941)(11,421)(19,637)(13,991)*(18,298)(22,332)(21,890)(21,516)*(27,301)(24,218)(23,458)
Interest income133*2563181,9521,735*2,4443,3892,9002,564*2,1812,0212,116
Interest expense34*31282522*20171412*864
Other income (expense)468*(13)(5)(7)(95)*(32)(48)(31)(8)*(113)(5)(1)
Income tax expense (benefit)377*—000*—9760254*—770
Net income (loss)(8,785)*(6,808)(12,671)(17,717)(12,373)*(15,906)(19,984)(19,035)(19,226)*(25,241)(22,285)(21,347)
Earnings per share, basic‡ USD per share—(0.28)(8.19)(2.26)—(0.93)(1.07)(1.02)(1.03)*(1.34)(1.18)(1.08)
Earnings per share, diluted‡ USD per share—(0.28)(8.19)(2.26)—(0.93)(1.07)(1.02)(1.03)*(1.34)(1.18)(1.08)
Weighted average shares, basic‡ thousands of shares—23,7391,5487,806—17,15818,68018,71318,718*18,76918,96419,704
Weighted average shares, diluted‡ thousands of shares—23,7391,5487,806—17,15818,68018,71318,718*18,76918,96419,704
  • ‡ Per-share figures and share counts are adjusted for the 1-for-1.8867924528301885 stock split (June 2024); filings made before it reported them unadjusted.
  • † Share count changed about 1/3 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (TECX's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents98,02090,481185,124159,095141,239306,246287,381268,435253,798236,894227,068234,666
Prepaid and other current assets1,9581,0742,2643,5035,6183,3973,4674,2192,9742,9974,0303,885
Total current assets100,26191,838187,388162,598146,857309,643290,848273,241257,359239,891231,098238,551
Property and equipment, net0—2,6392,5502,1511,9241,6831,4121,1851,020858793
Right-of-use asset4321101,2081,7672,2351,7241,2016658744,1083,6793,234
Total assets101,09392,348193,910168,717152,905314,829295,313277,001261,038246,577237,034243,860
Accounts payable272434,0902,6359766,2542,8041,4851,0932,5541,6771,624
Accrued liabilities5,4493,04220,00912,7377,8504,9076,8006,7507,3408,9737,1128,993
Total current liabilities6,3543,50926,00117,32011,61013,51011,3619,3739,66612,95810,36912,104
Lease liability, non-current0—90552313200003,1852,8192,431
Total liabilities6,3543,50927,54318,35612,12913,79311,5479,4739,70916,16013,18814,535
Accumulated deficit(477,275)(484,083)(118,496)(136,213)(148,586)(164,492)(184,476)(203,511)(222,737)(247,978)(270,263)(291,610)
Total stockholders' equity94,73988,839166,367150,361140,776301,036283,766267,528251,329230,417223,846229,325
Total liabilities and equity101,09392,348193,910168,717152,905314,829295,313277,001261,038246,577237,034243,860
Common shares outstanding (cover page)‡ thousands of shares23,77623,7947,8097,81918,66318,67318,71218,71618,77718,86919,54919,948
  • ‡ Per-share figures and share counts are adjusted for the 1-for-1.8867924528301885 stock split (June 2024); filings made before it reported them unadjusted.
  • † Share count changed about 1/3 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (TECX's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(8,785)*(6,808)(12,671)(17,717)(12,373)*(15,906)(19,984)(19,035)(19,226)*(25,241)(22,285)(21,347)
Stock-based compensation607*878(154)*1,650*1,117*2,1032,588*2,817*2,989*3,2054,012*4,235*
Depreciation and amortization0*0713*424*508*360340*342*333*304285*250*
Net cash from operating activities(8,031)*(7,569)(15,086)*(19,604)*(16,821)*(13,083)(14,719)*(17,815)*(14,461)*(18,413)(21,451)*(14,907)*
Purchases of property and equipment0*00*153*3*270*181*0*1979*0*
Net cash from investing activities150*00*(153)*(3)*(27)55*(166)*0*(19)(59)*0*
Proceeds from issuing common stock0*4——————————
Proceeds from issuing equity————————year only400,0000*0*
Net cash from financing activities59*30179,040*(6,287)*(1,069)*178,122(4,169)*(457)*(141)*84711,682*22,505*
Net change in cash(7,822)*(7,539)163,894*(26,029)*(17,856)*165,007(18,865)*(18,461)*(14,637)*(17,491)(9,826)*7,598*
  • † Share count changed about 1/3 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Tectonic Therapeutic234,666not reported(14,907)*19.9M12.8 quarters 10-QSep 30, 2026
Aldeyra Therapeutics40,975not reported(4,124)*60.4M— 10-QSep 30, 2026
Heron Therapeutics20,721not reported(2,213)*189.9M19.3 quarters 10-QJun 30, 2026
Sagimet Biosciences165,896not reported(11,099)*not reported23.2 quarters 10-QJun 30, 2026
Lifecore Biomedical23,03525,3226,946*37.9M— 10-QSep 30, 2026
Annexon199,270not reported(48,007)*not reported4.4 quarters 10-QJun 30, 2026
Precigen14,95974,14811,883*358.5M— 10-QSep 30, 2026
SELLAS Life Sciences Group138,343not reported(7,588)*201.9M18.2 quarters 10-QJun 30, 2026
DBV Technologies165,7001,600(51,500)*314.4M3.2 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.